Nsengi Ntamabyaliro, MD, MSc; UPC-PV, University of Kinshasa

SITE AND INVESTIGATOR SPOTLIGHT

This Site and Investigator Spotlight introduces Nsengi Ntamabyaliro, MD, MSc, from the Unit of Clinical Pharmacology and Pharmacovigilance (UPC-PV), University of Kinshasa, in Kinshasa, Democratic Republic of the Congo (DRC). FHI Clinical has worked with Dr. Ntamabyaliro on Phase 3 and 4 trials since 2007, at which time there was a focus on research capacity development in the DRC. Based on this history, FHI Clinical and Dr. Ntamabyaliro are currently collaborating with the UPC-PV on vaccine clinical trials and are working to identify opportunities to keep the research team active at the UPC-PV and the Kinshasa School of Public Health to sustain their research capacity.

Dr. Ntamabyaliro and UPC-PV were spotlighted in August 2022, and all information on this page is current as of then.

About Dr. Ntamabyaliro

Nsengi Ntamabyaliro is a medical doctor who specialized in pharmacoepidemiology and pharmacovigilance. Since 2007 and following his clinical practice in surgery and internal medicine, Dr. Ntamabyaliro has been involved in different roles in many clinical trials: supervisor, site coordinator, co-investigator and principal investigator. His research has focused primarily on malaria but has also included trypanosomiasis, monkeypox and Ebola. Dr. Ntamabyaliro worked as a member of the pharmacovigilance team during the study of EBANGA™, one of the two drugs currently approved by the FDA for the management of Ebola virus disease.

Determinants of Patients’ Adherence to Malaria Treatment in the Democratic Republic of the Congo. Tropical Medicine and Infectious Disease. July 2022
Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial. The Lancet: Microbe. May 2022
Therapeutic efficacy of artemisinin-based combination therapies in Democratic Republic of the Congo and investigation of molecular markers of antimalarial resistance. The American Journal of Tropical Medicine and Hygiene. September 2021
Knowledge of antimalarials and health seeking behaviour of households in case of suspected malaria in Democratic Republic of the Congo. Tropical Medicine and Infectious Disease. August 2021
Pyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study. PLoS Medicine. June 2021
Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo. Therapeutic Advances in Drug Safety. July 2019
The European Medicines Agency’s scientific opinion on oral fexinidazole for human African trypanosomiasis. PLoS Neglected Tropical Diseases. June 2019
Drug use in the management of uncomplicated malaria in public health facilities in the Democratic Republic of the Congo. Malaria Journal. May 2018

About UPC-PV

UPC-PV was created in 2008 with the missions of education, research and service to the nation in the field of clinical pharmacology, rational use of medicines and pharmacovigilance.

UPC-PV was accredited as a National Pharmacovigilance Centre of the DRC in 2009 with the responsibility of ensuring the safety of medicine use and monitoring of adverse drug reactions (ADRs) in the country.

Research interests include:

UPC-PV networks include:

Alliance for Clinical Research and Clinical Epidemiology in the DRC (ARCEAU)

Central Africa Clinical Research Network (CANTAM)

PALM Consortium

Human African Trypanosomiasis (HAT) Platform

The research site: Mount Amba Hospital Center

The Mount Amba Hospital Center is a reference hospital in the Lemba Health district that services five main areas surrounding the hospital and is close to the university hospital (~200 m).

Staff

Professors
Medical doctors who are specialists in pharmacoepidemiology, pharmacovigilance, epidemiology, clinical trials, vaccinology, internal medicine, neurology and pediatrics
Pharmacists
Lab techs and nurses with 10+ years of clinical trials experience

Primary diseases treated

Recent research

Facilities and capabilities

Two consultation rooms and four 4-bed patient rooms
Waiting space for 20+ patients
Nurse’s room
Air-conditioned laboratory with blood sampling, microscopy, hematology, biochemistry equipment
Refrigerators: -20°C; -40°C; -80°C

A new site under construction includes:

4 consultation rooms
4 large bed rooms for patients/participants
1 nurse’s room
1 large clinical laboratory
1 pharmacy
6 offices
1 meeting room

The disease profile of the DRC

Malaria

13%

The DRC is the second most affected country in the world: 11% of cases and 13% of deaths worldwide.

97%

The DRC has malaria transmission rates of 97%.

52%

Malaria accounts for 52.2% of admissions in the Mont Amba Health District.

Diarrheal diseases

6th

Diarrheal diseases are the 6th ranking cause of death in the DRC.

10 yrs

There has been no significant progress in the reduction of diarrheal diseases for the past 10 years.

3.2%

Diarrheal diseases account for 3.2% of admissions in the Mont Amba Health District.

Sickle cell disease

25%

25% of the population in DRC have the heterozygote sickle cell trait (carriers).

10-20%

10-20% of births have the heterozygote sickle cell trait.

2% of births have homozygote sickle cell (sickle cell anemia).

Future research:

Interventional and non-interventional studies
Continuing research for malaria, monkeypox and trypanosomiasis
Bacterial infections
Diarrheal diseases
Non-communicable diseases (e.g., diabetes, hypertension)

more site spotlights

Focus on Sites

Lucas Tina, MD, MPH; VIBRI and KEMRI

Kenya

Dr. Lucas Tina is affiliated with the Victoria Biomedical Research Institute (VIBRI) and Kenya Medical Research Institute (KEMRI) in Kisumu, Kenya. Dr. Tina serves as a Scientific Advisory Expert for FHI Clinical, and VIBRI and KEMRI are listed in FHI Clinical’s database of research sites.

Focus on Sites

Tariro Makadzange, MD, PhD; Charles River Medical Group, Pvt, Ltd (CRMG)

Zimbabwe

Tariro Makadzange, MD, PhD, is the Executive Director and Founder of Charles River Medical Group, Pvt, Ltd (CRMG), in Harare, Zimbabwe. CMRG is listed in FHI Clinical’s database of research sites.

Focus on Sites